Evogene (EVGN) Consolidated Net Income (2012 - 2026)
Evogene (EVGN) posted Consolidated Net Income of $14000.0 for Q1 2026, up 187.5% sequentially from -$16000.0 in Q4 2025, and up 101.29% YoY from $6955.2 in Q1 2025.
Evogene (EVGN) Consolidated Net Income (2012 - 2026) Analysis & Trends
Evogene has reported Consolidated Net Income for 15 years, with the latest figure at $14000.0 in Q1 2026.
- Quarterly Consolidated Net Income rose 101.29% year-over-year to $14000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.8 million (up 183.64% YoY) and the FY2025 annual result came in at $5.7 million, up 275.22% from the prior year.
- Consolidated Net Income grew to $14000.0 in Q1 2026 per EVGN's latest filing, from -$16000.0 in the prior quarter.
- Over five years, Consolidated Net Income peaked at $7.9 million in Q3 2025 and troughed at -$9.8 million in Q2 2022.
- A 5-year average of -$3.6 million and a median of -$3.8 million in 2024 frame the typical range for Consolidated Net Income.
- The sharpest annual moves came in 2023 and 2025: Consolidated Net Income slumped 92.02% in 2023, then soared 638.82% in 2025.
- Over 5 years, Consolidated Net Income stood at -$3.8 million in 2022, then sank by 92.02% to -$7.3 million in 2023, then soared by 86.53% to -$988000.0 in 2024, then jumped by 98.38% to -$16000.0 in 2025, then jumped by 187.5% to $14000.0 in 2026.
- According to Business Quant data, Consolidated Net Income over the past three periods registered $14000.0, -$16000.0, and $7.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | -5.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14,000.00 |
| Dec 31, 2025 | -16,000.00 |
| Sep 30, 2025 | 7.93 Mn |
| Jun 30, 2025 | -1.15 Mn |
| Mar 31, 2025 | -1.09 Mn |
| Dec 31, 2024 | -988,000.00 |
| Sep 30, 2024 | -1.47 Mn |
| Jun 30, 2024 | -4.55 Mn |
| Mar 31, 2024 | -3.85 Mn |
| Dec 31, 2023 | -7.34 Mn |
| Sep 30, 2023 | -3.86 Mn |
| Jun 30, 2023 | -7.78 Mn |
| Mar 31, 2023 | -6.98 Mn |
| Dec 31, 2022 | -3.82 Mn |
| Sep 30, 2022 | -7.16 Mn |
| Jun 30, 2022 | -9.75 Mn |
| Mar 31, 2022 | -9.11 Mn |
| Dec 31, 2021 | -8.08 Mn |
| Sep 30, 2021 | -8.34 Mn |
| Jun 30, 2021 | -6.90 Mn |